PHC Holdings

Lunaphore offers solutions based on a chip technology that can extract spatial proteomic and transcriptome data from tumors and other tissues, transforming any assay into multiplex spatial biology with an easy-to-use interface. Lunaphore enables immunology, immuno-oncology, and neurology researchers to push the boundaries of scientific discovery and therapeutic development. Lunaphore's technology identifies clinically relevant biomarker "signatures" to aid in the development of diagnostic tools and to streamline clinical trials, ultimately improving patient outcomes.

Lunaphore offers solutions based on a chip technology that can extract spatial proteomic and transcriptome data from tumors and other tissues, transforming any assay into multiplex spatial biology with an easy-to-use interface. Lunaphore enables immunology, immuno-oncology, and neurology researchers to push the boundaries of scientific discovery and therapeutic development. Lunaphore's technology identifies clinically relevant biomarker "signatures" to aid in the development of diagnostic tools and to streamline clinical trials, ultimately improving patient outcomes.

Aiforia Technologies, founded in 2013 as a spin-off from the Finnish Institute for Molecular Medicine at the University of Helsinki, specializes in cloud-based microscopy and pathology. The company offers the Aiforia® Platform, which combines deep learning artificial intelligence with high-performance cloud computing to enhance image-based diagnostics. Aiforia's solutions aim to increase efficiency and scalability in medical image analysis, supporting pathologists and scientists in both preclinical and clinical settings. By providing highly accurate and consistent data, Aiforia facilitates new discoveries and clinical decision-making across various disciplines, including oncology and neuroscience. The platform's image-agnostic capabilities allow it to extend its applications beyond traditional boundaries, positioning Aiforia as a leader in advancing medical imaging technology.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on developing innovative implantable CGM products, including the Eversense and Eversense XL systems, which measure glucose levels for up to 90 and 180 days, respectively. These systems utilize advanced fluorescence sensing technology to provide accurate and stable glucose monitoring, allowing users to manage their diabetes effectively. Senseonics primarily generates revenue from markets outside the United States, highlighting its commitment to enhancing the lives of people with diabetes through long-term, differentiated glucose management solutions.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on developing innovative implantable CGM products, including the Eversense and Eversense XL systems, which measure glucose levels for up to 90 and 180 days, respectively. These systems utilize advanced fluorescence sensing technology to provide accurate and stable glucose monitoring, allowing users to manage their diabetes effectively. Senseonics primarily generates revenue from markets outside the United States, highlighting its commitment to enhancing the lives of people with diabetes through long-term, differentiated glucose management solutions.

Lunaphore offers solutions based on a chip technology that can extract spatial proteomic and transcriptome data from tumors and other tissues, transforming any assay into multiplex spatial biology with an easy-to-use interface. Lunaphore enables immunology, immuno-oncology, and neurology researchers to push the boundaries of scientific discovery and therapeutic development. Lunaphore's technology identifies clinically relevant biomarker "signatures" to aid in the development of diagnostic tools and to streamline clinical trials, ultimately improving patient outcomes.

KAKEHASHI is the opportunity of Their foundation to want to become "Kakehashi connecting medical treatment and patients" "Kakehashi connecting medical care with a bright future". Japan is a country possessing world-class medical technology and medical system, it is a country with prominent longevity to be proud of in the world. In 2060, one in 2.5 people will enter an unprecedented super aging society of 65 years old and over, one in four will be over 75 years old. To think about the way of medical care that supports the healthy life expectancy in Japan is nothing but creation of the future image of Japanese society.

Ascensia Diabetes Care Holdings AG, based in Basel, Switzerland, specializes in the development and manufacturing of blood glucose monitoring systems, lancing devices, and diabetes management software. The company focuses on enhancing the lives of individuals with diabetes by providing innovative healthcare solutions that empower patients to manage their condition effectively. As a subsidiary of Panasonic Healthcare Holdings Co., Ltd., Ascensia Diabetes Care aims to support users in taking charge of their health and well-being through its comprehensive range of products.

Millennial Net's flagship platform, MeshScape, offers highly scalable, low power, reliable wireless mesh networking capability that is beyond any conventional WSN technologies. Millennial Net also provides Wireless Energy Management and Energy Efficiency solutions focused on commercial and public building applications. Typically save 15%-30% of a buildings current energy consumption.